Gene, 512, 232-236. http://dx.doi.org/10.1016/j.gene.2012.10.045Sevilla C, Moatti JP, Julian-Reyner C, Eisinger F, Stoppa-Lyonnet D, Bressac-de Paillerets B, et al. Testing for BRCA1 mutations: a cost effectiveness analysis. Eur J Hum Genet 2002;10:599 - 606....
Current practices and challenges in genetic testing and counseling for women with breast and ovarian cancer in Asia Aim: This study assesses current practices and challenges in genetic testing and counseling (GT and C) for breast cancer gene (BRCA)1/2 mutations in Asia, ... A Kwong,JM Ryu,...
What happens if you test positive for BRCA gene? Prior to undergoing testing, it is essential that women consider the benefits and risks in light of the possible results. For example, if her test is positive (meaning she is affected by agenetic disorder) there are measures that can reduce ...
Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. J Nat Cancer Inst. 2015;107(1):379. doi:10.1093/jnci/dju379Crossref 15. Gabai-Kapara E, Lahad A, Kaufman B, et al. Population-...
ARTICLE Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: A call for dialogue Wendy S. Rubinstein, MD, PhD1,2,3, Hongmei Jiang, PhD3,4, Lisa Dellefave, MS5, and Alfred W. Rademaker, PhD3,6 Purpose: About half of unaffected BRCA1/...
for Hereditary Breast and Ovarian Cancer Research September 25, 2024 Effects of Patient and Clinician Decision Support for BRCA1/2 Genetic Testing vs Standard Education Research July 18, 2022 Rare Pathogenic DNA Variants and Risk for Familial Clinical Disease Research April 29, 2020 Sign Up for ...
treatment of the overall AOC patient population and for homologous recombination deficiency (HRD)-positive patients, patients with a breast cancer susceptibility gene (BRCA) mutations, homologous recombination proficiency (HRD)-positive, or patients not harboring BRCA mutations AOC from a US payers ...
Pathogenic and clinically actionable variants were detected in RB1, TP53, BRCA2, APC, and 19 other genes. Analyses of larger batches indicated that our approach is highly scalable, yielding more than 95% cost reduction or less than 3 cents per gene screened for rare disease-causing mutations....
2023 Pertuzumab and Trastuzumab vs Trastuzumab for Treatment of Metastatic Breast Cancer Research February 28, 2022 Sign Up for Emails Based on Your Interests Others Also Liked We recommend Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis Nandini Dendukuri, ...
The current model of family history or clinical criteria–based gene testing for hereditary cancer is failing to reach many at-risk individuals who need it most, especially younger individuals. Targeted testing for BRCA1/2 has been reported to miss over 50% of at-risk individuals, even in high...